A decade of innovation in pharmaceutical R&D: the Chorus model
Authors:
- 15 December 2014
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 14 (1) , 17-28
Abstract
Chorus is a small, operationally independent clinical development organization within Eli Lilly and Company that specializes in drug development from candidate selection to clinical proof of concept. The mission of Chorus is to achieve proof of concept rapidly and at a low cost while positioning successful projects for 'pharma-quality' late-stage development. Chorus uses a small internal staff of experienced drug developers and a network of external vendors to design and implement chemistry, manufacturing and control processes, preclinical toxicology and biology, and Phase I/II clinical trials. In the decade since it was established, Chorus has demonstrated substantial productivity improvements in both time and cost compared to traditional pharmaceutical research and development. Here, we describe its development philosophy, organizational structure, operational model and results to date.Keywords
This publication has 24 references indexed in Scilit:
- Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake InhibitorCPT: Pharmacometrics & Systems Pharmacology, 2013
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survivalDrug Discovery Today, 2012
- An assessment of R&D productivity in the pharmaceutical industryTrends in Pharmacological Sciences, 2011
- The productivity crisis in pharmaceutical R&DNature Reviews Drug Discovery, 2011
- LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept studyArthritis & Rheumatism, 2010
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 DiabetesDiabetes Care, 2009
- Steven PaulNature Reviews Drug Discovery, 2009
- Public sector seeks to bridge 'valley of death'Nature Biotechnology, 2007